Vincristine Sulfate

Application Notes

Vincristine Sulfate is used to treat acute leukaemia, malignant lymphoma, Hodgkin′s disease, acute erythraemia, acute panmyelosis, breast cancer, Kaposi’s sarcoma and testicular cancer. It is widely used in cancer research. It is used to study multi-drug resistance. It is used to inhibit cell cycle progression at M-phase and to inhibit monoamine oxidase (MAO).

Usage Statement

Unless specified otherwise, MP Biomedical's products are for research or further manufacturing use only, not for direct human use. For more information, please contact our customer service department.

Key Applications

Antitumor agent | Treatment of acute leukaemia; malignant lymphoma; Hodgkin′s disease; acute erythraemia; acute panmyelosis; Breast cancer

SKU	02190687-CF
Alternate Names	22-oxo-vincaleukoblastine sulfate; Leuocristine sulfate (1:1); Vincrisul; VCR
Application Notes	Vincristine Sulfate is used to treat acute leukaemia, malignant lymphoma, Hodgkin′s disease, acute erythraemia, acute panmyelosis, breast cancer, Kaposi’s sarcoma and testicular cancer. It is widely used in cancer research. It is used to study multi-drug resistance. It is used to inhibit cell cycle progression at M-phase and to inhibit monoamine oxidase (MAO).
Base Catalog Number	190687
Beilstein Registry Number	3924631
Biochemical Physiological Actions	Vincristine is a plant alkaloid that inhibits microtubule assembly by binding tubulin and inducing coiled spiral aggregate formation. It arrests cell cycle in G2/M-phase by blocking mitotic spindle formation. Vincristine triggers Raf-1 activation, phosphorylation of bcl-2-family proteins, induction of p53 expression, and apoptosis in several tumor cell lines. It inhibits VEGF production in leukemia cell lines. It is a substrate for Pgp and CYP3A4. MRP1 transports vincristine in an ATP- and GSH-dependent manner. Vincristine has some immunosuppressant effect. Vincristine may also interfere with amino acid, cyclic AMP, and glutathione metabolism, calmodulin-dependent Ca2+-transport, cellular respiration, and nucleic acid and lipid biosynthesis.
CAS #	2068-78-2
EC Number	218-190-0
Format	Powder
Hazard Statements	H300-H341-H361fd
Melting Point	531Â° F approximately (NTP, 1992)
Molecular Formula	C46H58N4O14S
Molecular Weight	923.044 g/mol
RTECS Number	OH6340000
Safety Symbol	GHS06, GHS08
Solubility	greater than or equal to 10 mg/mL at 75Â° F (NTP, 1992)
Usage Statement	Unless specified otherwise, MP Biomedical's products are for research or further manufacturing use only, not for direct human use. For more information, please contact our customer service department.